Servier Pharmaceuticals Connects Healthcare Professionals Around pLGG at SNO 2026
Servier Pharmaceuticals/LinkedIn

Servier Pharmaceuticals Connects Healthcare Professionals Around pLGG at SNO 2026

Servier Pharmaceuticals shared on LinkedIn:

“Meaningful progress in pediatric low-grade glioma (pLGG) care starts with coming together as a community.

During SNO 2026, we had the opportunity to bring together healthcare professionals and advocates to connect and continue important conversations about how we can best support people living with pLGG.

We’re grateful to everyone who joined us and shared their perspectives. These conversations help deepen our understanding of the needs of the pLGG community and reinforce the importance of continued connection and collaboration.”

About Servier Pharmaceuticals

Servier is an international pharmaceutical group headquartered in France, with operations in more than 130 countries. Its U.S. business, Servier Pharmaceuticals, focuses mainly on oncology. The company also works in cardiometabolism, venous diseases and neurology.

In cancer research, Servier focuses on developing treatments for both solid tumors and blood cancers, including rare and difficult-to-treat conditions such as gliomas, colorectal cancer, pancreatic cancer and acute myeloid leukemia. Its work includes targeted therapies and immuno-oncology, with an emphasis on finding more personalized treatment options.

The company also collaborates with research institutions, biotech companies and healthcare professionals to support cancer research and improve treatment options for patients.

You may also be interested in: